MINDCURE’s proprietary line of integrative medicines, intended to balance the immune system and neurochemicals before and after psychedelic therapy, to be finalized in Q1
/NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR RELEASE PUBLICATION, DISTRIBUTION OR DISSEMINATION DIRECTLY, OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES./
VANCOUVER, BC, Jan. 26, 2021 /CNW/ – Mind Cure Health Inc. (CSE: MCUR) (OTCQB: MCURF) (FRA: 6MH) (“MINDCURE” or the “Company”) is pleased to announce it has moved out of development and is finalizing its proprietary formulation of all-natural integrative medicines intended to prepare and support patients of psychedelic therapies. MINDCURE’s Mindful Preparation and Mindful Integration pre- and post-treatment supplements are expected to be finalized in Q1 and available online to therapists and individuals through www.mindcurewellness.com and various partnership clinics around the world mid-2021 in both capsule form, as well as in personalized, daily powder packets.
As psychedelic-assisted therapy develops, MINDCURE is endeavoring to identify opportunities to better support patients undergoing treatment. By partnering with nutritional scientists and formulators in the supplements industry, MINDCURE’s goal is to become a leader in psychedelic therapeutic supports. These proprietary blends have been designed to help encourage an effective healing experience and to balance the brain’s natural chemistry before and after psychedelic treatment by using safe and natural ingredients. MINDCURE’s pre-treatment supplement, Mindful Preparation, is intended to enhance the therapeutic experience by promoting relaxation throughout the body, decreasing anxiety, balancing mood modifiers and enhancing sleep. MINDCURE’s post-treatment supplement, Mindful Integration, is intended to provide personalized support of mood, liver and blood health throughout the integration procedure following psychedelic therapy sessions.
“Our mission as innovators within the psychedelic space is to identify areas of care where visionary thinking and leadership can be applied to transform and improve the experience of healing. First, we recognized the opportunity for psychedelic therapy and innovative digital therapeutics with iSTRYM, and now we’re helping to ensure the best, individualized support possible for people throughout their healing journey,” said Kelsey Ramsden, President & CEO, MINDCURE.
About Mind Cure Health (MINDCURE) Inc.
MINDCURE exists as a response to the current mental health crisis and urgent calls for effective treatments. MINDCURE believes in the need to reinvent the mental health care model for patients and practitioners to allow psychedelics to advance into common and accepted care.
MINDCURE is focused on identifying and developing pathways and products that ease suffering, increase productivity, and enhance mental health. MINDCURE is interested in exploring diverse therapeutic areas beyond psychiatry, including digital therapeutics, neuro-supports, and psychedelics, all to improve mental health.
On Behalf of the Board of Directors
Kelsey Ramsden, President & CEO
Certain statements in this news release may constitute “forward-looking information” within the meaning of applicable securities laws (also known as forward-looking statements). Forward-looking information involves known and unknown risks, uncertainties and other factors, and may cause actual results, performance or achievements or industry results, to be materially different from any future results, performance or achievements or industry results expressed or implied by such forward-looking information. Forward-looking information generally can be identified by the use of terms and phrases such as “anticipate”, “believe”, “could”, “estimate”, “expect”, “feel”, “intend”, “may”, “plan”, “predict”, “project”, “subject to”, “will”, “would”, and similar terms and phrases, including references to assumptions. Some of the specific forward-looking information in this news release includes, but is not limited to, statements with respect to: MINDCURE’s development of pre and post-therapy integrative supplements called Mindful Preparation and Mindful Integration; MINDCURE’s Mindful Preparation and Mindful Integration supplements supporting and enhancing psychedelic-assisted therapy; Mindful Preparation and Mindful Integration being finalized by Q2 and available in mid-2021; Mindful Preparation and Mindful Integration being available to therapists through Health Center and global partner clinics; and Mindful Preparation and Mindful Integration being available in capsule and personalized powder packets.
Forward-looking information is based on a number of key expectations and assumptions made by MINDCURE, including, without limitation: the COVID-19 pandemic impact on the Canadian economy and MINDCURE’s business, and the extent and duration of such impact; no change to laws or regulations that negatively affect MINDCURE’s business; there will be a demand for MINDCURE’s products in the future; no unanticipated expenses or costs arise; MINDCURE will be able to continue to identify products that make them ideal candidates for providing solutions for treating mental health; that the functional mushroom industry will continue to grow; the addition of MINDCURE’s Mindful Preparation and Mindful Integration will help the company achieve its business goals; and MINDCURE will be able to operate its business as planned.
Although the forward-looking information contained in this news release is based upon what MINDCURE believes to be reasonable assumptions, it cannot assure investors that actual results will be consistent with such information.
Forward-looking information is provided for the purpose of presenting information about management’s current expectations and plans relating to the future and readers are cautioned that such statements may not be appropriate for other purposes. Forward-looking information involves significant risks and uncertainties and should not be read as a guarantee of future performance or results as actual results may differ materially from those expressed or implied in such forward-looking information. Those risks and uncertainties include, among other things, risks related to: the impacts of the COVID-19 pandemic on the Canadian economy, MINDCURE’s industry and MINDCURE’s business, which may negatively impact, and may continue to negatively impact, MINDCURE and may materially adversely affect MINDCURE’s investments, results of operations, financial condition, and MINDCURE’s ability to obtain additional equity or debt financing, and satisfy its financial obligations; general economic conditions; future growth potential; competition for mental health and wellness investments; the addition of MINDCURE’s Mindful Preparation and Mindful Integration may not help the company achieve its business goals; and changes in legislation or regulations. Management believes that the expectations reflected in the forward-looking information contained herein are based upon reasonable assumptions and information currently available; however, management can give no assurance that actual results will be consistent with such forward-looking information. Additional information on the risk factors that could affect MINDCURE can be found under “Risk Factors” in MINDCURE’s final prospectus which is available on SEDAR at www.sedar.com.
The forward-looking information contained herein is expressly qualified in its entirety by this cautionary statement. Forward-looking information reflects management’s current beliefs and is based on information currently available to MINDCURE. The forward-looking information is stated as of the date of this news release and MINDCURE assumes no obligation to update or revise such information to reflect new events or circumstances, except as may be required by applicable law.
The CSE has neither approved nor disapproved the contents of this press release and the CSE does not accept responsibility for the adequacy or accuracy of this release.
SOURCE Mind Cure Health Inc.
For further information: Connect: Investor Relations: email@example.com; 1-888-593-8995